Os Therapies Posts Wider Loss in Q2
Os Therapies (NYSEMKT:OSTX), a clinical-stage biotechnology company focused on immunotherapies for rare pediatric cancers, released earnings for Q2 2025 on August 19, 2025. The most important news in the release highlighted continued progress toward regulatory milestones for its lead drug candidate, OST-HER2, alongside deepening financial losses. Net loss per share was $0.19. Reported EPS of $0.19 was below the analyst estimate of -$0.12 per share for Q2 2025. No revenue was recorded in the period, aligning with consensus, as Os Therapies remains pre-commercial. Operating losses were approximately 2.9 times higher than in the second quarter of 2024, driven by ramped-up regulatory and clinical activity. Overall, the quarter showcased major advances for OST-HER2’s potential approval but underscored the company’s persistent need for capital and ongoing expense escalation.
Source: Analyst estimates for the quarter provided by FactSet.
Os Therapies develops immunotherapies to address untreated or under-treated forms of cancer, with a core focus on pediatric osteosarcoma. The company’s lead asset, OST-HER2, is an immunotherapy. This drug candidate targets a rare bone cancer that has seen little innovation in four decades. The business pursues accelerated development for OST-HER2, leveraging multiple FDA special designations that support quick regulatory review and potential market exclusivity.
Source Fool.com
